ライフサイエンスコーパス: short-acting

1 sfer) of high (metabolism-altering) doses of short-acting (0.5 U, once daily, regular, n = 13) or lon

2 cheduled to receive doxorubicin were given a short-acting 5-HT-receptor antagonist and dexamethasone

3 Short-acting 5-HT-receptor antagonists are no better tha

4 ptide levels were significantly reduced with short-acting (-56%, P = 0.01) and long-acting (-67%, P =

5 Short-acting agents (primarily those that increase heart

6 Monitors of depth of anesthesia, ultra-short-acting agents, and combined techniques have minimi

7 ut, at present, the majority of patients use short-acting agents.

8 ated with continuous delivery of levodopa or short-acting agonists, or with the use of long-acting ag

9 dy formation or their release in response to short-acting agonists.

10 suggests that further investigation of oral short-acting alpha4beta integrin blockade therapies is w

11 , 8), 17 (9), 19 (12, 13), or 41 (20) led to short acting analogues.

12 in human airway epithelia but were typically short acting and less effective in CF cultures with prol

13 Although short-acting and long-acting inhaled beta(2)-adrenergic

14 Short-acting and low doses of medium-acting muscle relax

15 nzodiazepine receptor agonist that is also a short acting anesthetic and analgesic drug, can produce

16 We have recently reported that the short-acting anesthetic and analgesic drug midazolam can

17 Despite widespread use of short-acting antagonists for the 5-hydroxytryptamine (5-

18 a(2)-adrenoceptor agonist (salbutamol) and a short-acting anticholinergic (ipratropium bromide), in C

19 Short-acting anticholinergic (SAAC) should be added to S

20 yses and 42 RCTs examined inhaled therapies: short-acting anticholinergics (n = 7), long-acting antic

21 nea management in advanced heart failure, or short-acting antidepressants in terminal illness.

22 teinuria, diabetic status, or greater use of short-acting antihypertensive agents in blacks versus wh

23 Triazolam is a short-acting benzodiazepine that results in phase advanc

24 r oral corticosteroids, >5 prescriptions for short acting beta agonists and more than four visits to

25 on to treat acute asthma exacerbation is the short-acting beta(2)-adrenergic receptor agonist; howeve

26 xperience with Combivent, a combination of a short-acting beta(2)-adrenoceptor agonist (salbutamol) a

27 A strong recommendation was made for using a short-acting beta(2)-agonist before exercise in all pati

28 ptoms of EIB despite the administration of a short-acting beta(2)-agonist before exercise, strong rec

29 asthmatics controlled with as needed inhaled short-acting beta(2)-agonists alone, and used bronchoalv

30 hma and who were symptomatic while receiving short-acting beta(2)-agonists alone.

31 sponses encountered with the clinical use of short-acting beta(2)-agonists.

32 Results demonstrate the efficacy of short-acting beta-agonist (SABA) delivered by metered-do

33 enance inhaled corticosteroids (ICSs) with a short-acting beta-agonist as a separate inhaler used whe

34 -required or "prn") use of a combination ICS/short-acting beta-agonist or ICS/long-acting beta-agonis

35 ints included FEV(1), symptom scores, rescue short-acting beta-agonist use, and exacerbations.

36 t infection and less than 2 puffs per day of short-acting beta-agonist; they also experienced a lower

37 lthcare services (51.7%, 511/988) and use of short-acting beta-agonists (55.2%, 545/988) was high.

38 tibiotics (ARR, 0.74 [95% CI, 0.35-1.57]) or short-acting beta-agonists (ARR, 0.95 [95% CI, 0.68-1.33

39 Allowed concomitant medications included short-acting beta-agonists and a systemic corticosteroid

40 t visits or hospitalizations, and (3) use of short-acting beta-agonists as quick-relief (sometimes re

41 of action substantially longer than that of short-acting beta-agonists, compared with ipratropium, a

42 All trials allowed the use of as-needed short-acting beta-agonists.

43 ta2-adrenergic receptor may not benefit from short-acting beta-agonists.

44 A short-acting beta-antagonist administered immediately af

45 defibrillation, and reperfusion and that the short-acting beta-antagonist esmolol administered at rep

46 thesia monitors and administration of potent short-acting beta-blockers and narcotics to control hemo

47 A short-acting beta1-selective adrenergic blocking agent,

48 The short-acting beta1-selective adrenergic blocking agent,

49 re of at least 1 for at least 2 days, rescue short-acting beta2 agonist use for at least 2 days, or n

50 Cells were cultured in the presence of the short-acting beta2-agonist albuterol, and the long-actin

51 h asthma, 68.4% received prescriptions for a short-acting beta2-agonist and 41.2% for inhaled cortico

52 s to assess the bronchodilator response to a short-acting beta2-agonist before and after chronic ther

53 dopamine receptor-beta2-agonist (n = 3), or short-acting beta2-agonist plus ipratropium (n = 3).

54 SQ-HDM [n = 282]) in addition to ICS and the short-acting beta2-agonist salbutamol.

55 hma being treated at least twice a week with short-acting beta2-agonist, alone or in combination with

56 Traditional inhaled short-acting beta2-agonists albuterol, fenoterol, and te

57 of aggravating environmental factors, use of short-acting beta2-agonists for rapid relief of symptoms

58 Inhaled short-acting beta2-agonists provide rapid relief of acut

59 rticosteroids (ICSs), leukotriene modifiers, short-acting beta2-agonists, oral corticosteroids, other

60 tient level predictors of poor control were: short acting bronchodilator overuse [2.129 (2.091; 2.164

61 lume in 1 s (FEV1) after administration of a short-acting bronchodilator has been widely used to iden

62 gers and built environment factors on asthma short-acting bronchodilator use.

63 An acute response to a short-acting bronchodilator, especially albuterol, predi

64 idence on the efficacy and safety of inhaled short-acting bronchodilators to treat asthma and wheeze

65 igh-flow oxygen, intravenous fluids, inhaled short-acting bronchodilators, and nebulized adrenaline.

66 .76 [95% CI 0.41-1.43]), whereas patients on short-acting calcium antagonists (n = 27) were at signif

67 Long-acting and short-acting calcium antagonists differ in cardiovascula

68 Short-acting calcium antagonists may increase coronary a

69 Other short-acting calcium antagonists such as diltiazem and v

70 Consistent with earlier findings, the use of short-acting calcium antagonists was associated with inc

71 anti-inflammatory drugs to 100% for avoiding short-acting calcium-channel blockers in patients with h

72 ports add to a growing body of evidence that short-acting calcium-channel blockers, whether used for

73 scular events associated with rapid release, short-acting CAs.

74 Short-acting contraception methods (eg, oral contracepti

75 ive adenosine receptor agonist WRC-0470 is a short-acting coronary vasodilator with potential utility

76 sociated with greater dosages of levodopa or short-acting DAs.

77 For several short-acting dihydropyridine calcium channel blockers, t

78 ng, but some case-control data, dominated by short-acting dihydropyridines, suggest an increased risk

79 Rather, levodopa or other short-acting dopaminergic drugs induce molecular changes

80 Because HCTZ has been perceived as a short-acting drug, a third comparison with an extended-r

81 This study examined whether the short-acting drug, propofol, could blunt the responses t

82 Tezosentan is an intravenous short-acting endothelin receptor antagonist that has fav

83 Using zolpidem (Ambien), a short-acting GABAA agonist hypnotic, we show increased s

84 Therefore zolpidem, a short-acting GABAAR modulator with selectivity for the t

85 The effects of propofol, a short-acting general anesthetic, upon cell growth and Ca

86 These observations suggest that short-acting GLP-1 agonists may be superior to long-acti

87 The short-acting glucagon-like peptide 1 receptor agonist ex

88 gnificant change in the number of claims for short-acting hormonal contraceptive methods during this

89 lined and there was a decrease in the use of short-acting inhaled beta2-stimulants, parenteral aminop

90 Short-acting inhalers for "rescue therapy" were not eval

91 Tirofiban is a highly selective, short-acting inhibitor of fibrinogen binding to platelet

92 o add exogenous bolus insulin therapy, using short-acting insulin analogs or regular insulin.

93 od glucose >/=140 mg/dl (treatment group) or short-acting insulin and/or oral antidiabetic agents for

94 tiated at 14 days post-transfer, whereas the short-acting insulin regimen did not retard the onset of

95 ISA, LSA, or CRA attributable to the type of short-acting insulin.

96 preparations, combining both long-acting and short-acting insulins, may be used.

97 Avaliable data on alternative short-acting local anaesthetics with respect to transien

98 h those induced by procaine (PRO 5 mg/kg), a short-acting local anesthetic with negligible effect on

99 European Trial-has compared carvedilol with short-acting metoprolol tartrate at different dose equiv

100 venous administration of an opioid drug (the short-acting mu receptor agonist, remifentanil) acquires

101 s to cocaine or heroin/prescription opioids [short-acting mu-opioid receptor (MOPr) agonists] involve

102 Short-acting nifedipine has no role in acute myocardial

103 0.137 mg/kg) linkers were also potent, ultra-short-acting NMBs with good to excellent selectivity ind

104 A single dose of the short-acting NMDA antagonist ketamine produces rapid and

105 A single sub-anesthetic dose of ketamine, a short-acting NMDA receptor blocker, induces a rapid and

106 nkeys for a novel mixed-onium class of ultra-short-acting nondepolarizing tetrahydroisoquinolinium ne

107 Methadone is widely used in treatment of short-acting opiate addiction.

108 ore suggest that prophylaxis with this ultra-short-acting opioid may be advantageous in various clini

109 ouch upon the possible benefits of the ultra-short acting opioids, and consider the role of alpha-2 a

110 ng therapeutic hypothermia may be a feasible short-acting option with potential postconditioning effe

111 ins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythrop

112 profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for trea

113 r PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors).

114 metabolic stabilization sufficient to obtain short-acting, potent, and selective 11beta-HSD1 inhibito

115 Short-acting pulsatile dopamine agonists are more likely

116 fter abdominal surgery (2 meta-analyses) and short-acting rather than long-acting intraoperative neur

117 study evaluated the efficacy and safety of a short-acting reduced-dose fibrinolytic regimen to promot

118 hat a selective, CNS-penetrant, peripherally short-acting, S1P(1) agonist would show full efficacy in

119 n and reduces cAMP production in response to short-acting (salbutamol) and long-acting (formoterol) b

120 asis by regulating the hindbrain response to short-acting satiety signals.

121 e either a long-acting (several hours) and a short-acting (several minutes) component to the mechanis

122 Drug testing programs must address short-acting stimulants, beta-blockers, and diuretics; t

123 Alfentanil, a rapid and short-acting synthetic analog of fentanyl, appears to of

124 modification led to the identification of a short acting triaminotriazine aniline methoxyamide (comp

125 n be achieved by the airway application of a short-acting vasodilator, such as prostacyclin.

126 ium antagonists, the adjusted risk ratio for short-acting versus long-acting was 8.56 (1.88-38.97), p